SERPINA7 Antibody (OASA09278)
- Known as:
- SERPINA7 Antibody (OASA09278)
- Catalog number:
- oasa09278
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- SERPINA7 Antibody (OASA09278)
Related genes to: SERPINA7 Antibody (OASA09278)
- Gene:
- SERPINA7 NIH gene
- Name:
- serpin family A member 7
- Previous symbol:
- TBG
- Synonyms:
- -
- Chromosome:
- Xq22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: SERPINA7 Antibody (OASA09278)
Related articles to: SERPINA7 Antibody (OASA09278)
- This prospective study evaluated first-trimester markers in pregnancies with isolated and combined forms of fetal growth disorders and gestational diabetes mellitus (GDM). Among 1869 screened women, the analysis included 83 controls, 55 GDM, 22 isolated intrauterine growth restriction (iIUGR), and 33 isolated large-for-gestational-age (iLGA) cases, with GDM subgroups stratified by fetal growth (GDM with normal fetal weight, GDM + IUGR, and GDM + LGA). First-trimester clinical and routine biochemical parameters were recorded, and serum concentrations of 80 proteins were measured using targeted LC-MRM-MS proteomics. Different trajectories emerged: IUGR phenotypes showed low PAPP-A/PlGF and high TSH ( < 0.01), indicating early placental insufficiency, while macrosomia showed opposite trends. GDM + IUGR represented the most severe "double hit" phenotype (lowest PlGF, earliest delivery), whereas GDM + LGA showed increased umbilical artery resistance despite excessive growth, suggesting endothelial dysfunction. Targeted proteomics revealed characteristic signatures: iIUGR featured low complement () and IGF proteins (, ) versus GDM and iLGA ( < 0.001); GDM + IUGR showed elevated and versus iIUGR ( < 0.05); GDM + LGA was marked by high and low , versus iLGA ( < 0.05). Complement and IGF pathways were consistently implicated. Machine learning achieved 77% sensitivity for IUGR prediction using clinical parameters and 88% sensitivity for LGA prediction using proteomic data. These findings demonstrate that fetal growth disorders represent pathophysiologically unique entities detectable in the first trimester, enabling early risk stratification and personalized management. - Source: PubMed
Publication date: 2026/05/08
Starodubtseva NataliaTokareva AlisaFrankevich NataliaKononikhin AlexeyBugrova AnnaIndeykina MariaKukaev EvgeniiDerenko AnnaFrankevich VladimirNikolaev EvgenySukhikh Gennady - Radiation pneumonitis (RP) is a dose-limiting toxicity in lung cancer radiotherapy, often poorly predicted by static clinical and dosimetric models. We aimed to identify a robust, blood-based proteomic signature grounded in the longitudinal biological response to radiation to enable accurate, early risk stratification. - Source: PubMed
Publication date: 2026/05/22
Lingyun WuNakamura MasakiToru MukoharaJing YangZeyu SunChunyun RenDeying ChenKan JiangQiuying TangKaikai DingXin YinHao YuYuzheng ZhouSiyuan WangJie YinYongheng YanYu HeQuanhai LiWeiWei Zhongjie LuXiaoli SunChiyuan MaXianghua YeSenxiang Yan - Inherited Thyroxine-binding globulin (TBG) deficiency is a rare X-linked disorder caused by mutations in the gene. This study aimed to investigate the underlying molecular defect in a hypothyroid patient undergoing levothyroxine (L-T4) therapy who exhibited persistent discordant thyroid function test (TFT) results and to characterise the structural and functional consequences of the mutation identified. - Source: PubMed
Publication date: 2026/03/25
Gawandi SmitaKhati HarshlataMalhotra GauravBaghel Nawab Singh - A certain population of patients exhibits discordant thyroid function tests (TFT) consistently along with unclear symptoms may lead to equivocal diagnosis and treatment. Concomitant elevation in TSH and T4 is one of the patterns of discordant TFT which can be associated with different thyroid-related conditions and, hence, warrants differential diagnosis. A case of congenital hypothyroidism was investigated to determine the etiology of the consistent co-elevation in TSH and T4 despite thyroxine supplementation since birth. T4 dose was changed multiple times which caused abrupt fluctuations in TSH and T4 levels in the previous treatment. The index patient, II-1 did not have pituitary or liver abnormality or any transient factors that would elevate thyroid hormone-binding proteins. The results revealed that II-1 had TBG-excess. However, no mutation or copy number variation in the gene which codes for TBG was detected. Further, II-1 was detected with a homozygous mutation, c.955G > A in the exon 8 of the gene associated with CH. His mother and siblings were heterozygous for the mutation, however, they had normal TBG and TFT. The present study is the first report of the rare combination of endocrine disorders i.e., TBG-excess and CH, and is also the first report of the mutation c.955G > A from Indian ethnic origin. The co-occurrence of two endocrine abnormalities caused TFT discordance and confusion. This study highlights the importance of detailed biochemical and genetic testing for the differential diagnosis of thyroid disorders in patients exhibiting discrepant TFT results which would avoid misdiagnosis and inappropriate treatment. - Source: PubMed
Publication date: 2024/03/15
Gawandi SmitaKumarasamy JKulkarni Savita - Early recognition of a risk of Alzheimer's disease (AD) remains a global challenge, and blood proteomic markers are of particular interest for wide-scale diagnostic use. Quantitative multiple reaction monitoring (MRM) approach demonstrates good reproducibility in the characteristic changes in the levels of reported candidate biomarkers (CBs) in different cohorts in AD. Following up on our previous study, we performed a joint analysis of 331 blood plasma samples from two different clinical cohorts of participants, comprising a total of 95 samples from patients with AD, 136 samples from patients with mild cognitive impairment (MCI), and 100 samples from controls. The obtained results confirm the significance of 37 CBs. A logistic regression-based algorithm was used to build protein classifiers, and a total of 21 important proteins were selected, 13 of which (ORM1, APOA4, LBP, HP, FN1, BCHE, APOE, PZP, A1BG, TF, SERPINA7, TTR, and F12) formed a universal panel that demonstrated strong classification performance in distinguishing AD patients from controls (ROC-AUC = 0.90) and in separating stable and progressing patients with MCI (ROC-AUC = 0.81). Overall, the analysis confirms the high potential of the MRM method for validating CBs in independent cohorts. - Source: PubMed
Publication date: 2025/12/19
Strelnikova Polina AKononikhin Alexey SZakharova Natalia VBugrova Anna EIndeykina Maria IFedorova Yana BKolykhalov Igor VMorozova Anna YAndryushchenko Alisa VFedoseeva Elena DEmelyanova Marina AGryadunov Dmitry AGavrilova Svetlana IMitkevich Vladimir AKostyuk George PChaika Yulia AMakarov Alexander ANikolaev Evgeny N